BIAF Overview

Sales Growth of CyPath® Lung: bioAffinity Technologies reported a 111% increase in test volume for its noninvasive lung cancer diagnostic test, CyPath® Lung, in October 2025 compared to the monthly average for the first nine months of the year, indicating strong adoption by physicians.

Clinical Value Recognition: The increase in test volume reflects growing recognition among clinicians of the test's clinical value in early lung cancer detection, particularly for patients with indeterminate pulmonary nodules.

Consistent Growth Trends: Throughout 2025, CyPath® Lung has shown consistent month-over-month and quarter-over-quarter sales growth, with a 95% increase in third-quarter sales compared to the previous quarter.

Technology and Accuracy: CyPath® Lung utilizes advanced flow cytometry and AI for detecting malignancy in sputum samples, achieving 92% sensitivity and 88% accuracy in clinical studies, which underscores its potential to improve early-stage lung cancer diagnosis and patient outcomes.

Stock Offering Announcement: bioAffinity Technologies, Inc. has completed a registered direct offering of 720,000 shares of common stock at $2.50 per share, with proceeds intended for working capital and to support sales growth of its noninvasive lung cancer test, CyPath® Lung.

Company Overview: bioAffinity Technologies focuses on noninvasive cancer diagnostics, with its primary product, CyPath® Lung, demonstrating high sensitivity and accuracy for early-stage lung cancer detection, marketed through its subsidiary, Precision Pathology Laboratory Services.

Stock Offering Announcement: bioAffinity Technologies, Inc. has completed a registered direct offering of 720,000 shares of common stock at $2.50 per share, facilitated by WallachBeth Capital LLC as the sole placement agent.

Use of Proceeds: The funds raised will be utilized for working capital, supporting sales growth for their noninvasive lung cancer test, CyPath® Lung, and for general corporate purposes.

Stock Offering Announcement: bioAffinity Technologies, Inc. has announced a registered direct offering of 720,000 shares of common stock at $2.50 per share, expected to close around October 9, 2025, with gross proceeds estimated at $1.8 million.

Use of Proceeds: The company plans to use the net proceeds for working capital, supporting sales growth of its noninvasive lung cancer test, CyPath® Lung, and for general corporate purposes.